APA (7th ed.) Citation

Buaboonnam, J., Rungmaitree, S., Piyaphanee, N., Charuvanij, S., Pitisuttithum, O., Copeland, K., . . . Chokephaibulkit, K. Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Buaboonnam, Jassada, et al. Immunogenicity and Safety of Tixagevimab-cilgavimab for COVID-19 Pre-exposure Prophylaxis in Immunocompromised 20 to <40 Kg Children and Adolescents: A Pilot, Prospective, Open-labeled Study. Taylor & Francis Group.

MLA (9th ed.) Citation

Buaboonnam, Jassada, et al. Immunogenicity and Safety of Tixagevimab-cilgavimab for COVID-19 Pre-exposure Prophylaxis in Immunocompromised 20 to <40 Kg Children and Adolescents: A Pilot, Prospective, Open-labeled Study. Taylor & Francis Group.